The HIV Netherlands Australia Thailand Research Collaboration
64
3
6
54
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
4.7%
3 terminated/withdrawn out of 64 trials
94.7%
+8.2% vs industry average
16%
10 trials in Phase 3/4
0%
0 of 54 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (64)
Towards a Functional Cure for HBV - The COMMIT Cohort Study
Role: collaborator
Improve Treatment Outcomes for Tuberculosis Infection in Tertiary Care Hospitals
Role: lead
A Prospective Cohort of Children With HIV Infection
Role: lead
Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals
Role: lead
A Long-term Follow-up of the HIV-NAT Cohort
Role: lead
Efficacy, Safety and Pharmacokinetics of DTG with RIF
Role: lead
Thailand HDV Cohort
Role: lead
Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolutegravir
Role: lead
Microneedles for Diagnosis of LTBI
Role: lead
FujiLAM Prospective Evaluation Trial
Role: collaborator
Dose Reduction of Lopinavir in Children
Role: lead
Pharmacokinetics of Generic Lopinavir/Ritonavir in Pregnant Women
Role: lead
Genotyping Directed Salvage Therapy in Children Who Have Failed Dual NRTIs
Role: lead
Therapeutic Drug Monitoring (TDM) in Generic Tenofovir/Lamivudine/Efavirenz
Role: lead
Efficacy and Safety of Single Versus Double Ritonavir-boosted Protease Inhibitor (PI)-Based Antiretroviral Therapy (ART) Regimens
Role: lead
Lopinavir (LPV) Dose Reduction
Role: lead
TDM of Generic Lopinavir/Ritonavir 200/50 mg
Role: lead
Pharmacogenomic of Atazanavir/Efavirenz (ATV/EFV)
Role: lead
Pharmacokinetics of Low Dose Raltegravir
Role: lead
Neurocognitive Impairment and Psychiatric Comorbidities in HIV-1
Role: lead